This report is based on information obtainedfrom a questionnaire sent to major cardiac centres in the United Kingdom. This produced details of 39 pregnancies in 34 patients after valve replacement. The 39 pregnancies gave rise to 30 healthy babies. The small size of the series probably reflects both the increasing rarity ofyoung women with rheumatic heart disease in this country and the cautious attitude of their cardiologists. This makes it likely that these women represented the best end of the spectrum of cardiacfunction after valve replacement.
that many of the publications may have been inspired either by the success or by the failure of the pregnancy or pregnancies described and might not be true indicators of overall practice and experience.
Patients
The questionnaire was sent to cardiologists in the United Kingdom and sought the following information.
(1) The patient's age, diagnosis, date of operation, and the interval between it and subsequent pregnancy; (2) the sites, models, and sizes of the artificial valves used: (3) the anticoagulant regimen adopted; (4) the use of other drugs including agents inhibiting platelet aggregation; (5) the course of the pregnancy with particular reference to the development of heart failure, valve dysfunction, embolism, or deep venous thrombosis; (6) the management of labour and the puerperium.
The section of the questionnaire which dealt with the baby inquired about (1) gestational age; (2) the general health at delivery; (3) the presence of congenital abnormalities, and (4) cerebral damage or jaundice.
The response to the questionnaire produced the details of 32 patients to which we added 5 of our own (Cases 5, 6, 7, 8, . The patients fell into 3 groups. The first group (Cases 1 to 30) consisted of patients who completed their pregnancies, 3 of whom have already been reported: Case 1 (Littler, 1970) ; Case 23 (Szekely and Snaith, 1969) , and Case 30 (Bennett and Oakley, 1968) . Nineteen patients were not given anticoagulants (Cases 1 to 19). Of these patients, 13 had homograft valves (6 aortic; 7 mitral), 1 an aortic fascia lata valve, 2 aortic Starr Edwards valves, 1 a Beall valve in the tricuspid position for Ebstein's disease, 1 a mitral homograft and a Starr Edwards aortic prosthesis, and 1 both mitral and aortic frame-mounted fascia lata valves. Eleven patients were treated with anticoagulants (Cases 20 to 30). These included 9 patients with Starr Edwards prostheses (7 mitral; 2 aortic), 1 with an Alvarez
Hammersmith mitral valve, and 1 with a mounted mitral homograft who was started on anticoagulants after an embolus at 34 weeks. Warfarin was used in 5 patients, 5 received phenindione, and 1 (Case 20) received subcutaneous heparin in full anticoagulant doses.
In the second group, pregnancy was not completed (Cases 31 to 34). Two of these patients had Starr Edwards prostheses and received warfarin. The other had a fascia lata mitral valve and was not given anticoagulants.
The third group consisted of 3 patients who had a 
Mothers
The maternal complications were few. The only patient who was treated with heparin throughout pregnancy rather than oral anticoagulants died. She was the only patient with a Hammersmith (Alvarez) prosthesis (Case 30); she received full anticoagulant doses of heparin subcutaneously throughout pregnancy and though she had enjoyed 3 years of good health since her valve replacement the valve became encapsulated by thrombus and fibrin when she was 33 weeks' pregnant (Bennett and Oakley, 1968) . In the second group, one patient who was on warfarin died at 32 weeks after rupture of a common iliac aneurysm; this was thought to be a complication of previous infective endocarditis (Case 34).
There was one maternal death in the third group and this resulted from postoperative complications following double valve replacement during the second trimester of pregnancy (Case 36). None of these major maternal complications can be attributed to the use of anticoagulants, though warfarin may have contributed to the fatal bleeding from the common iliac artery. There were 3 other minor complications attributable to anticoagulants: Cases 20 and 21 had postpartum haemorrhages and Case 22 developed a small haematoma of her abdominal wall after caesarian section. Apart from Case 30 there was only one thromboembolic complication in either group: Case 29 was in sinus rhythm with a mounted mitral homograft but had a cerebral embolus at 34 weeks; she was started on anticoagulants and the outcome was good.
The patients seemed to deal easily with the haemodynamic stresses of pregnancy and congestive failure was noted in only 2 patients. In neither was it a worry and both recovered well after a period of bed rest and diuretics. One was 35 years old with a mounted mitral valve prosthesis and atrial fibrillation (Case 10) and the other was a 33-year-old in sinus rhythm who was one of the only two patients in whom both mitral and aortic valves had been replaced, one of which was subsequently found to be leaking slightly (Case 17). Barnard and Heydenrych, 1969; Radnich and Jacobs, 1970; Jenkins and Braimbridge, 1971; Ibarra-Perez and Del Bosque-Ruiz, 1972 (Mahairas and Weingold, 1963; Palacios-Macedo, Dfaz-Devis, and Escudero, 1969; Laros, Hage, and Hayashi, 1970; Macdonald, 1970; Buxbaum et al., 1971; Jenkins and Braimbridge, 1971; Hirsh, Cade, and Gallus, 1972; Casanegra et al., 1975; Chew and Ratnam, 1975 When considering whether or not to continue oral anticoagulants the risk to the fetus if they are used has to be weighed against the risk of thromboembolism in the mother if they are stopped. Experience in non-pregnant patients indicates that anticoagulants are effective in reducing the incidence of thromboembolic complications after valve replacement (Akbarian et al., 1968) . During pregnancy the concentration of most coagulation factors in the blood is increased and fibrinolysis is decreased (Hedstrand and Cullhed, 1968) , but despite this there is little evidence of increased risk of pulmonary thromboembolism during normal pregnancy (Villasanta, 1965; Bonner, 1975) probably because of the increased cardiac output. There is a real risk of embolism in patients with prosthetic valves whose anticoagulants are stopped or interrupted during pregnancy (Akbarian et al., 1968; Jenkins and Braimbridge, 1971) (Isom et al., 1972) . The trend, which applies particularly to aortic prostheses, becomes more obvious the longer the valve is in situ and is attributed to endothelialization of the supporting structures of the prosthesis. Unfortunately, the protection from thromboembolic risk conferred by any of the newer artificial valves is not absolute. There is a higher incidence of embolism in patients with mitral than with aortic prostheses because these patients more frequently have atrial fibrillation and large atrial cavities and appendages. Ahticoagulants are mandatory in such patients but are still recommended in patients with aortic prostheses. Anticoagulants are usually not needed after tissue valve replacement. Thromboembolism is virtually unknown after free aortic homograft insertion and seems to be rare after replacement of the mitral valve with stented aortic homografts despite the frequency of atrial fibrillation. The only embolic episode in the series was in such a patient (Case 29) despite sinus rhythm when seen. The advantages of a biological valve in a young woman who may wish to have a family are apparent even though these valves may show less long-term durability than the artificial valves.
The formation of thrombus in relation to prostheses has been shown to be the result of the buildup of adherent platelet aggregates and the deposition of fibrin (Mustard et al., 1966) . This has led to the use of 'antiplatelet aggregating' agents, of which dipyridamole (Sullivan, Harken, and Gorlin, 1971) and aspirin (Stuart et al., 1974 ) have proved to be effective when combined with warfarin, but whether they will be safe in pregnancy or effective when used on their own has yet to be shown. There is one case report (Ben Ismail et al., 1975 ) of a woman with 3 prosthetic valves in whom warfarin was replaced by 1-5 g aspirin and 225 mg dipyridamole daily at 2 months' gestation and who continued to term with a successful outcome.
Oral anticoagulants of the coumarin and indanedione groups cross the placental barrier and reach the fetus whose state of anticoagulation is likely to be different from that of the mother as well as ummeasurable. Because of immature fetal liver enzyme systems the baby is likely to grow in a continuing state of anticoagulant overdose if the mother's state of anticoagulation is within the therapeutic range. It is probably more dangerous to give oral anticoagulants early in pregnancy because the fetus is then at its most vulnerable both from bleeding and from the teratogenic effects of these drugs (vide infra). A small haemorrhage can at this time produce severe damage because of the close proximity of the developing structures.
The evidence that these are real hazards comes from Mahairas and Weingold (1963) and the review by Villasanta (1965) later supported by Fillmore and McDevitt (1970) . Villasanta related the experience of 93 women who were treated with oral anticoagulants during their pregnancies, resulting in 14 stillbirths, 3 neonatal deaths, and 2 congenital malformations. He concluded that oral anticoagulant drugs should not be prescribed during pregnancy. Villasanta's experience that 16 per cent of the babies suffered brain damage attributable to haemorrhage in utero was particularly alarming as most of the mothers studied by him had received anticoagulants for venous thrombosis and so had only been treated for a few weeks rather than throughout pregnancy. The risk of intrauterine death was reported also by Palacios-Macedo et al. (1969) who described 3 stillbirths occurring in 6 patients with prosthetic valves, in 1 of whom multiple haemorrhages were found at necropsy and in another the fetus had probably died at a time when there was excessive anticoagulant effect in the mother. Poor anticoagulant control is likely to compound the risks. The case reported by Kenmure (1968) was an example of the kind of patient who fortunately does not appear in our series; in her 40s and diabetic with an accidental pregnancy, she had a mitral Starr valve and was in atrial fibrillation, with a history of postoperative cerebral embolism: the baby was stillborn at 33 weeks.
Mahairas and Weingold showed a connexion between depression of prothrombin activity and perinatal haemorrhage if oral anticoagulants were continued during delivery. Experimental evidence that the trauma of vaginal delivery is also a major risk factor in the production of perinatal cerebral haemorrhage is available from the work of Hirsh, Cade, and O'Sullivan (1970) who showed that widespread haemorrhage occurred in the fetuses of rabbits who were given warfarin until term; all were stillborn. In those cases reviewed by Villasanta (1965) who were receiving oral anticoagulants up to term there were 5 cases of perinatal haemorrhage, 4 of which proved fatal. Hirsh's group showed that no perinatal haemorrhage occurred if fetal clotting factors were allowed to return to normal by stopping warfarin a few days before delivery, or even in the presence of depressed fetal coagulation factors if delivery were by caesarian section. The usual practice now is for patients to have their oral anticoagulant changed to heparin, which does not cross the placenta, at least two weeks before term. This will not always be possible if labour starts prematurely, and vitamin K1 or fresh frozen plasma given to the mother may not have time to correct the depressed fetal clotting state before delivery. Premature labour may be an indication for caesarian section when the mother is on oral anticoagulant treatment.
Maternal bleeding requiring transfusion during labour is rare. There are 3 cases reported by Buxbaum et al. (1971) in association with the use of heparin. Haematomas in episiotomy sites or in caesarian scars (Case 22) do occur and show the need for scrupulous haemostasis (Hirsh et al., 1970 (Hirsh et al., , 1972 .
Anticoagulants need to be used, so what is the best regimen to adopt? Heparin throughout pregnancy would be expected to remove the fetal hazards but is not always a practical possibility. The use of self-administered subcutaneous injections of heparin have recently been shown (Bonner, 1975) to produce effective blood levels. Though its successful use in pregnancy has been reported (Otterson, McGranahan, and Freeman, 1968) and subcutaneous heparin has the advantage of allowing therapy to be controlled on an outpatient basis, its effectiveness during pregnancy is still unknown. Even though it was used in full anticoagulant dosage in Case 30 the results were disastrous. The lack of standardization of available heparin preparations is another problem (Jaques, 1975) . A compromise would be to use heparin in the first trimester, then to substitute oral anticoagulants until 2 to 3 weeks before term, when heparin is reintroduced. Hirsh et al. (1970) used this regimen in 15 pregnancies and had no fetal or neonatal complications. The obvious difficulty about this counsel of perfection would be the accurate prediction of the future conception in order to change the regimen in time.
Oral anticoagulant treatment is re-established after delivery. The presence of anticoagulant in the breast milk is not a significant problem compared with the higher concentration to which the baby had been exposed in utero. All babies should routinely be given vitamin K1 at birth.
Although the high fetal wastage can be attributed largely to the oral anticoagulant treatment it is not wholly consequent upon bleeding. A teratogenic effect of anticoagulants first suggested by Villasanta is now well substantiated. Stippled epiphyses have been reported in 7 babies after warfarin (Fourie and Hay, 1975; Pettifor and Benson, 1975; Becker et al., 1975; Shaul, Emery, and Hall, 1975) . This condition, also known as chondrodysplasia punctata or the Conradi-Hunermann syndrome, causes saddle nose deformity, nasal hypoplasia, frontal bossing, and short stature. Inconstant features include optic atrophy, cataracts, mental retardation, and flexion contractures. There was no definite example of this condition in our series except, possibly, for the baby of Case 35. It appears three times in the reports of pregnancy after valve replacement; DiSaia's (1966) patient whose baby had nasal hypoplasia and optic atrophy, Kerber, Warr, and Richardson's (1969) patient whose baby had nasal hypoplasia, and Tejani's (1973) patient whose baby had nasal hypoplasia and multiple neurological abnormalities. All 3 of these patients had received warfarin throughout the pregnancy until the 31st, 35th, or 36th week when heparin was substituted. According to Fourie and Hay (1975) , chondrodysplasia punctata is a rare embryopathy whose incidence has been estimated at 1 in 500 000 births and which otherwise is hereditary, occurring in a severe autosomal recessive and a milder autosomal dominant form. It 
